Chromium Chloride Hexahydrate

Chromium chloride hexahydrate (CrCl₃·6H₂O) is an inorganic trivalent chromium salt used primarily as a pharmaceutical-grade chromium source in Total Parenteral Nutrition (TPN) solutions for hospitalized patients. It delivers ionic Cr³⁺ to support trace mineral requirements when oral or enteral feeding is not possible, though no clinical efficacy data exists for its use as a standalone dietary supplement.

Origin & History

Chromium chloride hexahydrate (CrCl₃·6H₂O) is a synthetic inorganic compound that appears as green, violet, or reddish-violet deliquescent crystals. It is produced industrially as a water-soluble source of trivalent chromium (Cr³⁺) with a molecular weight of 266.44 g/mol. The compound is manufactured rather than extracted from natural sources and has high water solubility (59 g/100 mL at 20°C).

Historical & Cultural Context

No historical or traditional medicinal uses are documented for chromium chloride hexahydrate in any traditional medical systems. It is a modern synthetic compound used primarily in chemical synthesis, water treatment, catalysis, and plating applications rather than traditional medicine.

Health Benefits

• No documented health benefits - the research provides no human clinical trials, RCTs, or meta-analyses for this compound as a biomedical ingredient
• Limited to use as a chromium source in Total Parenteral Nutrition (TPN) solutions - no efficacy data provided
• No therapeutic evidence documented in the available sources
• No biomedical mechanisms or pathways described
• Functions solely as a chemical reagent and industrial compound rather than a health supplement

How It Works

Chromium chloride hexahydrate dissociates in aqueous solution to release trivalent chromium ions (Cr³⁺), which are proposed to potentiate insulin signaling by facilitating insulin receptor tyrosine kinase activation, possibly through a low-molecular-weight chromium-binding oligopeptide called chromodulin. Chromodulin is hypothesized to bind Cr³⁺ and interact with the insulin receptor to amplify downstream phosphorylation cascades involving IRS-1 and PI3K pathways. However, this mechanism remains incompletely characterized in human physiology, and the bioavailability of inorganic CrCl₃ is extremely low, estimated at less than 1% of ingested dose.

Scientific Research

The research dossier reveals a complete absence of human clinical trials, randomized controlled trials, or meta-analyses for chromium chloride hexahydrate as a biomedical ingredient. No PubMed PMIDs, sample sizes, or therapeutic outcomes are documented in any of the sources. The compound is referenced only as a sterile additive for Total Parenteral Nutrition without accompanying clinical evidence.

Clinical Summary

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted specifically using chromium chloride hexahydrate as a biomedical or dietary supplement ingredient. Its documented clinical use is strictly limited to intravenous TPN formulations, where it serves as a chromium additive at doses typically ranging from 10–15 mcg/day for adults, as recommended by the American Society for Parenteral and Enteral Nutrition (ASPEN). Evidence supporting general chromium supplementation for glucose metabolism, insulin sensitivity, or weight management comes from studies using other forms such as chromium picolinate or chromium polynicotinate, and cannot be extrapolated to this compound. The overall evidence base for any chromium form in healthy individuals remains weak and inconsistent across the published literature.

Nutritional Profile

Chromium Chloride Hexahydrate (CrCl₃·6H₂O, molecular weight ~266.45 g/mol) is an inorganic chromium(III) salt providing trivalent chromium (Cr³⁺) as its sole bioactive mineral constituent. Each molecule yields approximately 19.5% chromium by weight (i.e., ~52.0 g Cr per 266.45 g compound). It contains no macronutrients (zero protein, fat, carbohydrate, or fiber), no vitamins, and no organic bioactive compounds. The compound also provides chloride ions (~39.9% by weight, ~3 Cl⁻ per molecule). In pharmaceutical/clinical settings, it is typically supplied as a sterile solution at concentrations of 4 mcg Cr³⁺/mL (equivalent to ~20.5 mcg CrCl₃·6H₂O/mL) for addition to Total Parenteral Nutrition (TPN) admixtures. The recommended daily TPN supplementation provides 10–15 mcg of elemental chromium for adults, with the adequate intake (AI) for chromium generally cited at 20–35 mcg/day for adults. Bioavailability considerations: when delivered intravenously via TPN, bioavailability is effectively 100% since gastrointestinal absorption is bypassed entirely. By contrast, oral bioavailability of inorganic chromium(III) salts is extremely poor, estimated at only 0.4–2.0% of ingested dose. Chromium from this compound is not chelated or complexed with organic ligands (unlike chromium picolinate or chromium nicotinate), which contributes to its low oral absorption. The compound provides no antioxidant capacity, no polyphenols, no amino acids, no essential fatty acids, and no dietary fiber. It is hygroscopic, freely soluble in water, and dissociates completely in aqueous solution to release Cr³⁺ and Cl⁻ ions. No other trace minerals or contaminants are present in pharmaceutical-grade preparations. It is classified strictly as a mineral/trace element source rather than a nutritional supplement with broad nutrient content.

Preparation & Dosage

No clinically studied dosage ranges are available for oral forms such as extract, powder, or standardized versions. The compound is used solely in intravenous Total Parenteral Nutrition as a chromium source, but specific doses are not detailed in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no synergistic ingredients identified due to lack of supplement use

Safety & Interactions

Chromium chloride hexahydrate administered intravenously in TPN has a well-documented safety profile at physiological doses (10–15 mcg/day for adults), but excess intravenous chromium can accumulate in tissues including the liver and kidneys, posing toxicity risks in patients with renal or hepatic impairment. Oral ingestion of inorganic chromium salts like CrCl₃ is generally considered low-risk due to extremely poor gastrointestinal absorption (<1%), but high oral doses may cause gastrointestinal irritation. Potential drug interactions include reduced chromium absorption when co-administered with antacids containing calcium carbonate or magnesium hydroxide, and NSAIDs such as indomethacin and aspirin may increase chromium absorption unpredictably. Chromium chloride hexahydrate should not be used as a self-administered supplement during pregnancy without medical supervision, as safe supplemental dosing beyond established adequate intake levels (29–30 mcg/day for pregnant women) has not been studied.